Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

The role of CD95 and CD95 ligand in cancer.

Peter ME, Hadji A, Murmann AE, Brockway S, Putzbach W, Pattanayak A, Ceppi P.

Cell Death Differ. 2015 Apr;22(4):549-59. doi: 10.1038/cdd.2015.3. Epub 2015 Feb 6. Review. Erratum in: Cell Death Differ. 2015 May;22(5):885-6.

2.

Prognostic value of the Fas/Fas ligand system in breast cancer.

Bębenek M, Duś D, Koźlak J.

Contemp Oncol (Pozn). 2013;17(2):120-2. doi: 10.5114/wo.2013.34612. Epub 2013 Apr 29.

3.

Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients.

Drescher KM, Sharma P, Lynch HT.

Clin Dev Immunol. 2010;2010:170432. doi: 10.1155/2010/170432. Epub 2010 Jun 10. Review.

4.

Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden.

Guillen-Ahlers H, Suckow MA, Castellino FJ, Ploplis VA.

PLoS One. 2010 Feb 5;5(2):e9070. doi: 10.1371/journal.pone.0009070.

5.

Expression of TNF-related apoptosis-inducing ligand (TRAIL) in keratinocytes mediates apoptotic cell death in allogenic T cells.

Reimers K, Radtke C, Choi CY, Allmeling C, Kall S, Kiefer P, Muehlberger T, Vogt PM.

Ann Surg Innov Res. 2009 Nov 19;3:13. doi: 10.1186/1750-1164-3-13.

6.

Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells.

O'Callaghan G, Kelly J, Shanahan F, Houston A.

Br J Cancer. 2008 Aug 5;99(3):502-12. doi: 10.1038/sj.bjc.6604490. Epub 2008 Jul 22.

7.

Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression.

Yamana K, Bilim V, Hara N, Kasahara T, Itoi T, Maruyama R, Nishiyama T, Takahashi K, Tomita Y.

Br J Cancer. 2005 Sep 5;93(5):544-51.

8.

Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.

Zhang W, Ding EX, Wang Q, Zhu DQ, He J, Li YL, Wang YH.

World J Gastroenterol. 2005 Jun 21;11(23):3632-5.

9.

Tumour-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction.

Heath RM, Jayne DG, O'Leary R, Morrison EE, Guillou PJ.

Br J Cancer. 2004 Apr 5;90(7):1437-42.

10.

Cytotoxic reactions of CC531s towards liver sinusoidal endothelial cells: a microscopical study.

Vekemans K, Timmers M, Vermijlen D, Zanger RD, Wisse E, Braet F.

Comp Hepatol. 2004 Jan 14;3 Suppl 1:S49. No abstract available.

11.

Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression.

Houston A, Bennett MW, O'Sullivan GC, Shanahan F, O'Connell J.

Br J Cancer. 2003 Oct 6;89(7):1345-51.

12.

Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases.

Backus HH, Van Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters D, Pinedo HM, Peters GJ.

J Clin Pathol. 2002 Mar;55(3):206-11.

Supplemental Content

Support Center